Application of a novel, rapid, and sensitive oligonucleotide ligation assay for detection of cancer-predicting mutations in the precore and basal core promoter of hepatitis B virus. by Mendy, Maimuna E et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
International Health and Tropical Medicine Articles Department of International Health and TropicalMedicine
1-8-2008
Application of a novel, rapid, and sensitive
oligonucleotide ligation assay for detection of
cancer-predicting mutations in the precore and
basal core promoter of hepatitis B virus.
Maimuna E. Mendy
Medical Research Council, Banjul
Steve Kaye
Medical Research Council, Banjul
Emilie Le Roux
International Agency for Research on Cancer, Lyon
Gregory D. Kirk
Johns Hopkins University
Adam Jeng-Barry
Medical Research Council, Banjul
See next page for additional authors
This Article is brought to you for free and open access by the Department
of International Health and Tropical Medicine at e-publications@RCSI. It
has been accepted for inclusion in International Health and Tropical
Medicine Articles by an authorized administrator of e-publications@RCSI.
For more information, please contact epubs@rcsi.ie.
Citation
Mendy ME, Kaye S, Le Roux E, Kirk GD, Jeng-Barry A, McConkey S, Cotten M, Kuniholm MH, Leligdowicz A, Hainaut P, Rowland-
Jones S, Whittle H. Journal of Clinical Microbiology. 2008;46(8):2723-30.
Authors
Maimuna E. Mendy, Steve Kaye, Emilie Le Roux, Gregory D. Kirk, Adam Jeng-Barry, Samuel McConkey,
Matthew Cotten, Mark H. Kuniholm, Aleksandra Leligdowicz, Pierre Hainaut, Sarah Rowland-Jones, and
Hilton Whittle
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/ihtmart/9
— Use Licence —
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/ihtmart/9
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2008, p. 2723–2730 Vol. 46, No. 8
0095-1137/08/$08.000 doi:10.1128/JCM.01622-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Application of a Novel, Rapid, and Sensitive Oligonucleotide Ligation
Assay for Detection of Cancer-Predicting Mutations in the Precore
and Basal Core Promoter of Hepatitis B Virus
M. E. Mendy,1* S. Kaye,1† E. Le Roux,2 G. D. Kirk,3 A. Jeng-Barry,1 S. McConkey,1‡ M. Cotten,1
M. H. Kuniholm,3 A. Leligdowicz,1 P. Hainaut,2 S. Rowland-Jones,1 and H. Whittle1
Viral Diseases Programme, Medical Research Council, Banjul, The Gambia1; Molecular Carcinogenesis, International Agency for
Research on Cancer, Lyon, France2; and Department of Epidemiology, Johns Hopkins University Bloomberg School of
Public Health, Baltimore, Maryland3
Received 14 August 2007/Returned for modification 21 November 2007/Accepted 17 May 2008
Hepatocellular carcinoma (HCC) and cirrhosis are important causes of mortality worldwide. Persistent
hepatitis B virus (HBV) infection is a major cause of these diseases. Double mutations in the basal core
promoter (BCP) (A1762T and G1764A) and precore (pre-C) (G1896A) regions of the virus are associated with
progression to HCC. The current study is aimed at developing a simple method for screening and detecting
BCP and pre-C mutations in HBV carriers. We have developed and validated an oligonucleotide ligation assay
(OLA) to detect point mutations in the HBV core gene. We have applied OLA methods to samples from
HBV-infected carriers recruited from the Gambia Liver Cancer Study (GLCS) comprising asymptomatic
HBsAg carriers, patients with cirrhosis, and patients with HCC. We observed an 89.3% and 95.8% concordance
between the OLA and DNA sequencing for BCP and pre-C mutations, respectively. OLA detected the mutations
in single-strain infections and in infections with mixtures of wild-type and mutant viruses under conditions
where sequencing detected only the single dominant strains. BCP mutations were detected in 75.7% of patients
with advanced liver disease (cirrhosis/HCC) compared to 47.6% of asymptomatic carriers, while pre-C muta-
tions were detected in 34.5% of advanced liver disease patients and in 47.6% of asymptomatic HBsAg carriers.
There was a significant association between the presence of BCP mutations and advanced liver disease. In
conclusion, OLA is a simple, economical, and reliable assay for detection of pre-C and BCP mutations. Its
application can lead to improvement in diagnosis and clinical care in regions where HBV is endemic.
Chronic hepatitis B virus (HBV) infection is a major health
problem worldwide, particularly in sub-Saharan Africa (22).
The prevalence of the HBV carrier state in unvaccinated Gam-
bians is 15 to 20% (35). Chronic HBV carriers are at high risk
of developing hepatocellular carcinoma (HCC), the most im-
portant cause of cancer morbidity and mortality in many parts
of the world including Asia and sub-Saharan Africa. Fifty-three
percent of HCC cases worldwide are related to HBV (31).
HCC is the most common cancer in Gambian men and the
second most common in Gambian women, with HCC inci-
dence rates of 61.0 and 55.7 per 100,000, respectively (1).
Although the development of primary liver cancer frequently is
associated with persistent HBV infection (4), the contribution
of HBV to the pathogenesis of HCC is multifactorial and is
complicated by the involvement of HBV mutants (MTs) that
are capable of modulating the carcinogenesis process (6).
HBV is a small DNA virus with a 3.2-kb, partially double-
stranded, relaxed circular genome and contains four overlap-
ping open reading frames (pre-S/S, precore [pre-C]/core, poly-
merase, and X gene) (25). The pre-C region encodes the HBV
e antigen (HBeAg), which has been used clinically as an indi-
cator of active viral replication and proposed to have an im-
munoregulatory role in natural infection (38). The enhancer II
(EnhII) and basal core promoter (BCP) reside in the overlap-
ping X gene. The HBx protein is capable of transactivating
HBV promoters (37). EnhII/BCP play an important role in the
viral replicative cycle by regulating the formation of the pre-
genomic RNA which is important for the production of the
viral core and polymerase proteins and HBeAg (25). Several
nucleotide alterations that frequently occur in the BCP/EnhII/
pre-C regions have been identified, but their effects on the
development of HCC are unclear.
The predominant mutation in the pre-C region involves a
G-to-A alteration at nucleotide 1896, changing a tryptophan
codon (TGG) into a premature stop codon (TAG) at codon 28
(10). Such pre-C variants were first described in Mediterra-
nean patients with significant liver disease in the absence of
HBeAg (7).
Mutations in the BCP at nucleotide 1762 (A1762T) and
nucleotide 1764 (G1764A) have been described elsewhere (8).
These mutations result in coding changes at codons 130 and
131 in the HBX protein changing lysine to methionine and
valine to isoleucine, respectively. The relationship between
these pre-C/BCP MTs, serum HBV DNA levels, and the se-
verity of liver disease is unclear (15, 23, 27). Although the
pre-C and BCP MTs have been found in asymptomatic carriers
in Africa (11), there are limited data on the association of
these MTs with the development of HCC in sub-Saharan
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Africa, mainly because currently available detection methods
are expensive and require laboratory facilities and equipment
not commonly available in this region. A study in South Africa
conducted on 50 HCC patients and 47 asymptomatic HBsAg
carriers reported BCP prevalence rates of 66% and 11%, re-
spectively (3). In another study, the pre-C region was se-
quenced in sera from 27 HCC patients from The Gambia and
33 asymptomatic HBsAg carriers. Fourteen (52%) patients
compared to 12 (36%) asymptomatic carriers were found to
harbor the pre-C MT (20).
Three methods are currently available for detecting HBV
genome variants: the point mutation assay, the line probe as-
say, and direct DNA sequencing. The point mutation assay is
either a radioactivity-based technique (16) or a colorimetric
assay (2). The line probe assay will reliably identify pre-C
mutation but has a low sensitivity in detecting BCP mutation
(9). The use of the oligonucleotide ligation assay (OLA) was
demonstrated by Tobe et al. as a typing assay for two alleles in
a single microtiter well (33). Later, Edelstein et al. developed
a high-throughput OLA method for the detection of mutations
in patients with human immunodeficiency virus type 1 (HIV-1)
(12). More recently OLA has been used to detect mutations
causing reverse transcriptase inhibitor resistance (Q151M and
M184V) in HIV-2-infected Gambian patients (17). The overall
sensitivity of OLA in detecting mutations in HIV among Gam-
bian patients was 98.8% with 99.2% concordance compared to
sequencing. Minor variants, when present in mixtures of wild-
type (WT) and MT viruses, were detected in cases where
sequencing detected only the major population.
We have developed a novel point mutation assay using the
OLA methodology for the detection of single base changes in
the pre-C and BCP region of HBV. The HBV OLA was vali-
dated against consensus sequencing of the serum HBV DNA
derived from asymptomatic carriers and from patients with
HBV-related liver disease. We assessed the potential of OLA
as a screening tool in carriers at risk of developing HCC.
MATERIALS AND METHODS
Subjects. The study used stored serum samples from the Gambia Liver Cancer
Study conducted in The Gambia between 1997 and 2001 (18). The inclusion
criterion for the OLA study was positivity for HBsAg. The study used samples
from 138 HCC patients, 49 cirrhosis patients, and 40 HBV-infected asymptom-
atic HBsAg carriers. HCC and cirrhosis cases were confirmed by clinical exam-
ination, ultrasound, and histology or -fetoprotein (AFP) level. Asymptomatic
HBsAg carriers were HBV carriers who had no evidence of liver disease, and
they served as controls in the study.
AFP was detected and quantified by a standard radiometric assay (DiaSorin
SA, Sallugia, Italy), as previously described (18). HBsAg was determined as a
marker of chronic HBV carriage by reverse passive hemagglutination assay
(Murex Diagnostics Limited, Dartford, United Kingdom) with radioimmunoas-
say testing of negative samples (Sorin Biomedica Diagnostics, Vercelli, Italy).
Participants positive for HBsAg were tested for HBV “e” antigenemia (HBeAg)
as a surrogate marker of active replication using a radioimmunoassay kit (Dia-
Sorin).
PCR amplification of the HBV core region. HBV DNA was extracted from 200
l of serum using the QIAamp DNA minikit (Qiagen, United Kingdom). Ex-
tracted DNA was amplified in nested PCRs to generate a 274-bp fragment
encoding HBV nucleotides 1674 to 1947 encompassing the basal core, pre-C, and
core regions of the viral genome. The first-round PCR mixture contained 20
picomoles of primers HBV1 and HBVR1 (Table 1), 5 l of DNA extract equiv-
alent to 10 l serum, and 12.5 l of HotStar PCR Master Mix (Qiagen, United
Kingdom) in a final PCR volume of 25 l. Cycling conditions were 95°C for 15
min (1 cycle); 94°C for 30 seconds, 58°C for 30 seconds, and 72°C for 1 min (35
cycles); and a final extension at 72°C for 7 min. The second round of PCR used
primers CPREF1 and CPRER1, the same reaction mix, and the same cycling
conditions except for an annealing temperature of 55°C. Samples that were
negative after the first nested PCR using the outer and inner primers were
repeated using only the inner primers (CPRF1 and CPRER1) to obtain shorter
fragments, and two rounds of 35 cycles were performed as described above with
an annealing temperature of 55°C.
OLA probes. OLA probes were designed against the core gene sequence of
genotype E (ayw4) (GenBank accession number X75657) (28). Ligation primers
specific for WT sequences were labeled at the 5 end with digoxigenin; MT-
specific primers were labeled with fluorescein. The common oligonucleotide
TABLE 1. Primers and probes used in PCR amplification and OLAs
Primer or probe Positions in HBV genome Sequenceb
Nested PCR primers for HBV core amplificationa
HBV1 (OF) 1246–1266 5-TTTGTGGCTCCTCTGCCGATC-3
HBVR1 (OR) 2322–2300 5-GATAAG ATAGGGGCATTTGGTGG-3
CPRF1 (IF) 1674–1694 5-TCTGCAATGTCAACGACCGAC-3
CPRER1 (IR) 1947–1927 5-AGTAACTCCACAGTAGCTCCA-3
M3 (sense) 1730–1747 5-CTGGGAGGAGTTGGGGGA-3
5C (antisense) 2466–2486 5-CCCACCTTATGAGTCCAAGG-3
Probes for mutation type
Pre-C
1896G 1876–1896 Dig-5-GCTGTGCCTTGGGTGGCTTTG-3
1896A 1876–1896 Fluo-5-GCTGTGCCTTGGGTGGCTTTA-3
1896/Com 1897–1917 2-Phos-5-GGGCATGGACATTGACCCTTA-3 biotin
BCP
1762AE 1741–1762 Dig-5-CGGGGGAGGAGATTAGATTAAA-3
1762TE 1741–1762 Fluo-5-CGGGGGAGGAGATTAGATTAAT-3
1762 ComE 1763–1784 Phos-5-GRTCTTTGTACTAGGAGGCTGTA-3 biotin
1764GE 1741–1764 Dig-5-CGGGGGAGGAGATTAGATTAAWGG-3
1764AE 1741–1764 Fluo-5-CGGGGGAGGAGATTAGATTAAWGA-3
1764 ComE 1765–1785 3-Phos-5-TCTTTGTACTAGGAGGCTGTA-3 biotin
a OF, outer forward; OR, outer reverse; IF, inner forward; IR, inner reverse.
b Bases comprising the codons of interest are in boldface. Dig, digoxigenin; Phos, phosphorylated; Fluo, fluorescein.
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which hybridizes downstream of the WT and MT was labeled at the 3 end with
biotin and phosphorylated at the 5 end (Table 1). This primer anneals to
nucleotides in the specific regions of the HBV pre-C/BCP gene immediately
adjacent to the 3 end of both the MT and WT genomes.
OLA. An equivalent of 10 l of serum was used in PCR amplification (total
reaction volume of 25 l); 2 l of the PCR mixture was then used in the OLA
reaction. Thus, the amount of patient serum used in the OLA reaction is ap-
proximately 12.5 times less than that used in the PCR amplification. All tests
were performed in duplicate, and ligation assays were performed according to
published protocols (5, 12) utilizing a reaction mixture containing 1 ligase
buffer (100 mM MgCl2, 10 mM dithiothreitol, 10 mM NAD [Sigma, United
Kingdom], 80 mM KCl [Sigma], 0.1% Triton X-100), 3 U of thermostable ligase
(Epicentre Technologies, United Kingdom), and 3 pmol of each ligation primer.
Detection of MT and WT genotypes was achieved by using a streptavidin-
coated microtiter plate and the simultaneous addition of anti-digoxigenin-per-
oxidase (Boehringer Mannheim) and anti-fluorescein-alkaline phosphatase
(Boehringer Mannheim) followed by sequential washing and addition of Gibco
enzyme-linked immunosorbent assay (ELISA) amplification system (Invitrogen)
and tetramethylbenzidine substrate (Promega) to detect MT and WT sequences,
respectively. The optical densities (ODs) were measured using a Multiscan
Ascent ELISA plate reader (Thermo Labsystems, Finland) at wavelengths of 490
nm and 450 nm for MT and WT, respectively.
The cutoff values for the OLAs were obtained by testing 30 replicates of
MT-positive samples. The standard deviations of the ODs for the positive WT
samples in the MT assay (OD at 490 nm [OD490]) and the MT samples in the WT
assay (OD450) were multiplied by 3. For example, 3  standard deviation for
OLA 1896 is 0.1 and that for the OLA 1762/1764 is 0.25. Thus, following this
experiment, 0.1 (OLA 1896) and 0.25 (OLA 1762) were added to the mean ODs
of the negative samples to obtain the cutoff values. It was also possible to read the
plates visually, as this may be important for resource-poor settings where ELISA
plate readers are not easily available (data not shown). Samples were considered
MT (magenta and positive OD490), WT (yellow and positive OD450), or mixed
WT and MT if magenta and yellow (plus positive OD490 and OD450) were
obtained in the MT and WT assays, respectively.
DNA sequencing. Following a DNA extraction method similar to that indi-
cated for the OLA, HBV basal core, pre-C, and core gene regions were amplified
prior to DNA sequencing using primers M3 and 5C (Table 1) (11). To avoid
contamination, samples that tested negative for markers of HBV (anti-HBc and
HBsAg) were used as negative controls and were included in each experiment.
The same controls were included in every step: DNA extraction, PCR amplifi-
cation, and OLA reaction.
PCRs were carried out using HotStar Taq (Qiagen, United Kingdom) in a
mixture containing 2.5 l of 10 buffer, 5 l of 5 Q solution, 1 l of de-
oxynucleoside triphosphate (5 mM), 1 l each of primers (20 picomoles/l) M3
and 5C, 0.2 l of HotStar Taq (5 g/l), and 5 l of the DNA (100 to 300 g/l).
The thermocycling conditions were 95°C for 15 min followed by 45 cycles of 94°C
for 30 s, 55°C for 30 s, 72°C for 1 min, and 72°C for 7.0 min. The PCR products
(5 l) were purified with 1.5 l of ExoSAP-IT (Amersham) by incubation for
15.0 min at 37°C and 15.0 min at 80°C.
DNA sequencing was performed using the Big Dye Terminator v1.1 cycle
sequencing kit reaction mix containing 1.5 l PCR product, 1.25 l of 5 buffer,
1 l of 5 M primer, and 30 cycles of 95°C for 10 s, 50°C for 5 s, and 60°C for
4.0 min. Samples were sequenced in both directions, and consensus sequences
were obtained from alignment of the forward and reverse sequences.
Analysis of DNA sequences. Seventy-six DNA sequences obtained from nine
asymptomatic HBV carriers, 15 cirrhosis patients, and 52 HCC cases were
aligned with genotype E (X75664 and X75657) reference sequences obtained
from GenBank (28) using the DNAstar Lasergene program. Nucleotide varia-
tions at positions 1762, 1764, and 1896 were compared with the reference se-
quences.
HBV viral load measurement. Serum HBV DNA load was measured using a
real-time PCR technique as previously described (26).
Statistical analysis. Statistical analysis was performed using STATA 8.0 (Col-
lege Station, TX) and SAS 9.1 (SAS Institute, North Carolina). The sequence
data were transferred into Excel spreadsheets for analysis of the selected codons.
Comparisons between OLA and sequencing were made using two-tailed 2
analysis, Fisher’s exact test, and the Wilcoxon-Mann-Whitney test. Statistical test
differences were considered significant if P values were 0.05. Comparisons
between viral DNA quantity and dichotomous groups (the three study groups,
HBsAg, HBeAg, BCP, and pre-C mutations) were made using the Wilcoxon-
Mann-Whitney test.
RESULTS
Performance of OLA. There was no overlap in the ranges of
OD readings for the positive and negative controls. In general,
samples that tested negative (260 DNA copies/ml) in the
PCR amplification assay were also negative in the OLA. The
lower detection limit of the OLA was derived as follows: DNA
was extracted from 100 l of serum containing 2.4  108
copies/ml and eluted into 50 l buffer, 5.0 l (equivalent to 10
l serum) was added into the pre-OLA mixture, and the PCR
amplification reaction (total volume of mixture, 25 l) was
performed. A 2.0-l amount of the PCR mixture was used in
the OLA (equivalent to 0.8 l serum). Six serial dilutions
containing between 2.4  108 and 2.4  103 DNA copies/ml
were tested and resulted in a detection limit of 2.4  104
copies/ml or 19.2 copies/OLA reaction.
The lower (i.e., more sensitive) detection limit of DNA ob-
served in the quantitative PCR (qPCR) assay compared to
OLA could be due to limitations on OLA template prepara-
tion, i.e., probe mismatch and nonspecific inhibitors.
Assay validation. The sensitivity of OLA for detecting mi-
nority populations of MT virus was determined by assaying
serial dilutions of MT DNA amid a constant amount of WT
DNA. The DNA samples used in the mixtures tested positive
for MT alone or WT alone in both OLA and DNA sequencing
assays and were considered as pure MT or WT. A positive MT
sample with a DNA quantity of 4.8 108 copies/ml was serially
diluted into a solution containing 3.7  106 copies/ml WT
DNA. By mixing equal volumes of 2.4  108 copies/ml of MT
DNA and 3.7  106 copies/ml of WT DNA, we obtained a
mixture of approximately 98% molecules of MT DNA. Addi-
tional dilutions were prepared containing 88% (2.4  107 cop-
ies), 39% (2.4  106 copies), 6.1% (2.4  105 copies), 0.6%
(2.4  104 copies), and 0.06% (2.4  103 copies) MT DNA in
a constant amount of WT DNA (Table 2). The lower detection
limit for MT sequence was 2.4  104 copies/ml amid 3.7  106
TABLE 2. MT (G1896) and WT (A1896) detection in mixtures of
the WT and MT strainsa
IND
sample
Concn of MT in mixture
(no. of copies/ml)
% of MT
in mixture
Expt
no.
OD reading
MT WT
1 MT alone (2.4  108) 100 1 1.29 0.26
2 1.44 0.21
2 WT alone (3.7  106) 0 1 0.49 3.43
2 0.44 3.61
3 2.4  108 98 1 0.98 2.02
2 1.01 2.10
4 2.4  107 90 1 1.45 3.01
2 1.31 3.11
5 2.4  106 40 1 1.33 3.13
2 1.24 3.36
6 2.4  105 6.1 1 1.21 3.40
2 1.10 3.10
7 2.4  104 0.6 1 1.02 3.45
2 0.98 3.34
8 2.4  103 0.06 1 0.48 3.40
2 0.46 3.20
a Samples 3 to 8 contain various concentrations of MT sequences diluted in a
constant amount of WT (3.7  106 copies/ml). Mixtures were tested with both
the MT and WT probes. The cutoff values obtained in this assay were 0.53 for
MT and 0.56 for WT.
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copies WT DNA. We also found that WT sequence was de-
tectable in the mixture containing 98% MT sequences as well
as in those with lower amounts of MT (Table 2).
The performance of the assay in detecting MT in samples
with a single strain was determined by testing samples of MT
DNA diluted in water and compared with detection of MT
diluted in WT DNA. The sample was OLA and sequencing
positive for MT alone. The limit of the assay in detecting the
target MT was 2.4  104 copies/ml in the MT/WT mixture and
2.4  105 in the MT/water mixture. The reduced sensitivity of
the assay when MT was diluted in water compared to MT
dilution in WT DNA is possibly due to loss of DNA in very
dilute solutions, or perhaps the presence of WT contributes to
the lower limit of detection and in the absence of WT the limit
of detection increases by a log.
Comparison of OLA with direct DNA sequencing. One hun-
dred one HBsAg-positive subjects were selected for DNA se-
quencing; 25 had undetectable virus (260 DNA copies/ml) in
the qPCR assay; they failed to generate PCR products and
were therefore not tested for OLA. DNA samples from the
remaining 76 subjects (52 HCC patients, 15 cirrhosis patients,
and nine asymptomatic HBsAg carriers) were tested for BCP
mutations by both OLA and direct DNA sequencing of the
PCR fragment. The sensitivity of OLA in detecting the A1896,
T1762, and A1764 MTs was 94.2%, 89.7%, and 89.5%, respec-
tively, and the specificity of the assay was 97.3%, 88.2%, and
90.4% in detecting the A1896, T1762, and A1764 MTs, respec-
tively (Table 3).
Samples that had mixed strains and tested positive for both
WT and MT in the OLA were considered indeterminate
(IND), while in the DNA sequencing assay IND was defined as
the presence of a nucleotide other than WT or MT in the
target region.
Three (3.9%) out of the 76 samples were IND by sequenc-
ing, and seven (9.2%) were IND in the OLA (Table 4). Thus,
the OLA detected a significantly higher proportion of IND
samples than did sequencing (P  0.05). Similarly there was a
higher proportion of BCP IND than of pre-C IND samples.
This was true for both DNA sequencing and OLA, i.e., five
TABLE 3. Comparison of OLA and sequencing methods for
detecting MTs
OLA (nucleotide position)
and result type
No. of results found by sequencing
WT MT IND Total
1896
WT 37 1 1a 39
MT 2 33 35
IND 1b 1
Total 76
1762
WT 15 2 5a 22
MT 5 44 49
IND 5b 5
Total 76
1764
WT 19 2 1a 22
MT 5 43 48
IND 6b 6
Total 76
a Sequencing assay.
b OLA.
TABLE 4. Samples with IND or negative OLA results, their corresponding viral loads, nucleotide sequences in the target regions, and
sequence changes in one, two, or three bases from the target regionsa
OLA and
expt no.
Result
type
Viral load (no. of
copies per ml) DNA sequence
Change(s) in one, two, or three
bases from target
Pre-C
1 IND 1.5  107 MT None
2 IND 3.6  104 MT None
3 Negativeb 2.8  102 WT G1899A
4 Negative 3.3  102 MT G1899A
5 Negative 5.9  102 WT
6 Negative 3.7  102 MT
BCP
7 IND 1.2  105 T1762T/G1764 None
8 IND 6.5  103 WT None
9 IND 4.3  105 MT T1768A
10 IND 3.6  104 WT None
11 IND 1.0  105 T1762/T1764 None
12 Negative 1.2  107 A1762/T1764 None
13 Negative 2.5  105 WT G1763A, C1766G
14 Negative 1.7  107 WT T1765G, C1766T
15 Negative 7.0  102 WT None
a Samples 3 to 6 and 15 had viral loads of 103 DNA copies/ml, which is lower than the detectability limit of the OLA. The OLA detected mixtures of WT and MT
in samples 1, 2, 8, 9, and 10, while consensus sequencing detected the dominant strain. Sequences in positions 1762 and 1764 are discordant in sample 7, with the
presence of MT in position 1762 and WT in 1764. Samples 13 and 14 are negative in the OLA because of the nucleotide changes in one, two, or three bases from the
target region, although consensus sequencing revealed WT sequences. Sample 11 was OLA positive for MT 1762 and WT 1764; the discordant result was due to a
mixture of MT T1762 and T1764. The two polymorphisms are different from the WT or MT sequences. Nucleotide 1762 or 1764 in sample 7 or 12 is neither WT nor
MT, hence the IND/negative result in the OLA.
b “Negative” represents samples with no visible color change in either the MT or the WT assay.
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(6.5%) BCP IND samples compared to no pre-C IND samples
in the DNA sequencing assay and 6.5% (5/76) BCP IND sam-
ples compared to 2.6% (2/76) pre-C IND samples in the OLA.
Three OLA IND samples (samples 1, 2, and 10), although they
had viral loads above the limit of detection, tested positive for
MT alone or WT alone in the DNA sequencing assay. The
discrepancy between DNA sequencing and OLA in these sam-
ples could be due to infection with mixed virus strains and
suggests reduction in the sensitivity of the DNA sequencing
assay in detecting minor virus sequences in mixed infections.
However, another two OLA IND samples (T1762/G1764 and
T1762/T1764) were confirmed by DNA sequencing (Table 4).
Eight of the 76 sequences are OLA negative but PCR pos-
itive (260 DNA copies/ml). Three of them had base changes
located at one to four bases from the ligation sites, which are
expected to prevent binding and ligation. An additional OLA-
negative sample had a DNA concentration of 1.2  107 copies
but had a change other than the specific mutation (1764T) in
the target region which would disrupt OLA primer binding
(Table 4).
Application of OLA. Blood samples collected from 227 HBsAg
carriers (138 HCC patients, 49 cirrhosis patients, and 40
asymptomatic HBsAg carriers) were tested for the pre-C and
BCP mutations by OLA. Details of the subject recruitment are
described above, with additional details being previously pub-
lished (18). Forty-four samples (15.8%) had undetectable
DNA (260 copies/ml) in the qPCR assay, while 183 and 178
samples gave valid results for pre-C or BCP mutation, respec-
tively (Table 5). Five samples were not tested for BCP.
In the OLA pre-C mutation assay, 36.5.1% (66/183) and
63.9.4% (117/183) tested positive for MT and WT, respec-
tively. Thirteen (7.1%) individuals had IND results, while 31
(16.9%) failed genotyping; they were OLA negative (i.e., the
color representing neither WT nor MT failed to appear).
Twenty-six of these 31 (14.2%) had DNA values lower than the
OLA detection limit (260 to2.4  104 DNA copies/ml) but
higher than the PCR detection limit. Another five (2.7%)
OLA-negative samples were positive by PCR with HBV DNA
levels of 2.4  104 to 1.7  107 copies/ml.
The pre-C mutation was not associated with disease; the
variant is detected in 36.9% (44/119) of HCC patients, 27.9%
(12/43) of cirrhosis patients, and 47.68% (10/21) of asymptom-
atic HBsAg carriers (P 	 0.241, Table 5).
In the OLA BCP assay, 72.4% (129/178) and 27.5% (49/178)
of the subjects tested positive for MT and WT, respectively
(Table 5). A significantly (P 	 0.01 for HCC and P 	 0.02 for
cirrhosis) higher proportion of individuals with HBV-related
liver disease than of asymptomatic carriers had the BCP mu-
tation. BCP mutations were detected in 75.4% (86/114) of
HCC subjects, 76.7% (33/43) of cirrhotic subjects, and 47.6%
(10/21) of asymptomatic HBsAg carriers (Table 5).
DISCUSSION
We have developed a simple OLA-based point mutation
assay to detect pre-C and BCP mutations in chronic HBV
carriers. Having optimized and validated the OLA assay, we
used it to study sera from a well-characterized HCC case con-
trol study. The assay, which included DNA extraction from
serum PCR amplification of a region of the HBV core gene,
ligation of oligonucleotides, and color development, can be
readily performed within 1 working day. The OLA allows large
numbers of samples to be handled with ease and speed and
thus has the potential to be used for rapid screening.
Apart from rapidity and economy, another advantage of the
OLA method in genotyping point mutations compared to
other genotypic approaches and DNA sequencing is the high
ease of interpretation of ligation assays; the assay yields clearly
positive or negative outcomes that are easy to interpret visually
or that can be interpreted by a spectrophotometer and com-
puter program with samples on microtiter plates.
The reproducibility of the assay is very good as demon-
strated by the consistent results obtained from 30 WT, MT, or
IND samples that were tested on two (25 samples) or three (5
samples) separate occasions (data not shown). The assay can
detect MT DNA with a lower detection limit of 19.2 copies per
reaction. OLA has the important feature of being able to
detect a low amount of MT DNA (2.4  104 copies/ml) amid
a high amount of WT (3.7  106 copies/ml). Thus, MT se-
quences can be detected when they constitute only 0.6% of the
total HBV sequence concentration, improving the screening
potential of the assay, as it will facilitate early detection of MT
HBV genomes that may presage HCC development.
As expected, due to the highly specific nature of OLA, the
assay produced inconclusive or negative results when tested
against nucleotide sequences other than the WT or the specific
TABLE 5. Viral polymorphisms in liver disease patients and asymptomatic HBsAg carriersa
Subject group (n)
Result for OLA
1896 1762/1764
No. (%) of subjects
P
No. (%) of subjects
P
WT Pre-C MT WT BCP MT
Asymptomatic HBsAg carriers (21) 11 (52.3) 10 (47.6) 0.5 11 (52.3) 10 (47.6) 0.5
HCC patients (119 for OLA 1896, 114 for
OLA 1762/1764)
75 (63.0) 44 (36.9) 0.356 28 (24.6) 86 (75.4) 0.01
Cirrhosis patients (43) 31 (72.1) 12 (27.9) 0.119 10 (23.2) 33 (76.7) 0.02
Total (183 for OLA 1896, 178 for OLA
1762/1764)
117 66 49 129
a Two hundred twenty-seven subjects were originally included in the study; 44 had undetectable viral DNA (260 DNA copies/ml) and tested negative in the OLA.
Data from the remaining 183 are presented here. The prevalences of pre-C and BCP mutations in patients with liver diseases, i.e., HCC and cirrhosis, were 34.5% and
75.7%, respectively (P  0.01).
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MT form. The specificity of the assay was reduced when it was
used with samples bearing additional changes in nucleotide
positions located one to four bases from the target site. For
example, DNA sequencing of two OLA-negative samples re-
vealed 1762T/1764T and 1762T/1762G sequences. This is po-
tentially a disadvantage; however, once a study population has
been characterized, a panel of oligonucleotides covering all
possible mutations can be readily prepared.
The discordant results between DNA sequencing and OLA
in the samples that had mismatches of nucleotides 1762 and
1764 but were clearly OLA positive for MT alone or WT alone
likely reflect the higher sensitivity of OLA in detecting specific
point mutations (Fig. 1). Although sequencing is the gold stan-
dard that was used in this study, it has limitations in detection
of minority sequences. We found that where a sequence was
clearly pure WT or MT, OLA did not disagree with the gold
standard sequencing but in the case of minor MT or WT
populations OLA was able to detect these when sequencing
was unable. Although the testing of artificial mixtures of WT
and MT (Table 2) shows some evidence that OLA is superior
to sequencing in detecting minor populations, we plan to per-
form sequencing and OLA on multiple clones from samples
with mixed populations that are detectable by OLA but not by
sequencing to further develop this assay.
It has been previously shown that although the identification
of novel mutations is more readily obtained by consensus se-
quencing, OLA is more sensitive for the detection of specific
variants within a mixed virus population in drug resistance
mutation studies of HIV-1 infection (13). Another important
advantage of the OLA method is that it can detect both WT
and MT sequences in a population of mixed strains (Table 2)
(17). We detected 0.6% of MT amid WT sequences, unlike
consensus sequencing, which will detect only the predominant
virus in a mixed infection.
OLA samples reactive in both WT and MT OLAs are clas-
sified as IND, and further investigation including sequencing
of clones will be needed to confirm mixed populations and to
fully correctly characterize all viruses present.
Some samples failed to provide a clear OLA signal (i.e., no
WT or MT signal resulting in negative results). Predominantly,
this occurred in cases of insufficient target DNA arising from
low copy numbers in samples, suggesting that samples with
very low input copy numbers can affect the accuracy of OLA.
We previously observed that a DNA quantity of 261 copies
per ml can be measured in the samples by qPCR (26). How-
ever, the OLA was unable to genotype 16.9% (31/183) of
PCR-positive samples despite having target DNA concentra-
tions within the detection range. These false-negative results
are most likely to be caused by probe-target mismatch in sam-
ples with low copy numbers of HBV DNA. This may be a
limitation to our assay compared to DNA sequencing and alter-
native methods using specific primers in real-time PCR quantifi-
cation (30). False-negative results could also be due to insertions,
deletions, or duplications in the target region (19, 21).
The lower sensitivity could not be explained by lower sample
viral load since a number of untypeable samples had viral loads
of up to 107 copies/ml.
As an important demonstration of the utility of this new
method, the clinical significance of the presence of HBV pre-C
and BCP mutations was assessed in samples for our previous
case control study.
We found that patients with liver diseases (cirrhosis or
HCC) were significantly more likely to have the BCP mutation
than were asymptomatic carriers.
FIG. 1. Alignment of samples with WT, MT, discordant, and IND results. Nucleotide differences from X75664 (reference genotype E sequence
obtained from GenBank) are shaded in black.
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The association of BCP mutations with HCC obtained in our
study compared well with results from a study in Taiwan con-
ducted on 200 HCC patients and 160 infected chronic HBV
asymptomatic HBsAg carriers (24). The frequency of the BCP
mutation in the Taiwanese study was 76.9% in patients with
HCC and 14.4% in chronic carriers with a statistically signifi-
cant odds ratio for the BCP mutation (P  0.001). The con-
clusion from that study was that of the factors examined (age,
sex, HBV genotype, viral load, and pre-C mutations) the BCP
mutation is the strongest independent predictor for the devel-
opment of HCC. Our data also demonstrate a strong associa-
tion of the BCP mutation with HBV-associated liver disease.
The higher overall proportion of asymptomatic carriers with
BCP mutations in the Gambian population assessed herein
than in the Taiwanese population could be related to different
HBV genotypes circulating in the two countries. In The Gam-
bia genotype E is predominant at 87.3% with genotype A
occurring at 12.7% (27). The importance of genotypic differ-
ences is highlighted in the Taiwanese study, where genotype C
was associated with a significantly higher incidence of BCP
mutations than was genotype B. It is still unclear whether the
pre-C mutation has any pathogenic role for more severe dis-
ease, although it was initially thought to cause more severe
liver disease because it was found in patients with active liver
diseases or fulminant hepatitis (29). However, in our study, the
pre-C mutation was not associated with advanced HBV-related
liver disease, consistent with results from several prior studies
(14).
AFP, which is a widely used marker for HCC detection
because of its ease of use and low cost, suffers from low spec-
ificity and sensitivity, being elevated in diseases other than liver
cancer and absent in a proportion of confirmed HCC cases (32,
34, 36). Further studies are needed to determine the role of
molecular biomarkers such as BCP mutations and HBV geno-
types. These markers can be used in combination with other
biomarkers as a reliable screening tool with HBV chronic car-
riers at risk of developing HCC.
In conclusion, we have developed a simple, economical, and
reliable assay for detecting HBV core mutations. This point
mutation assay may be extremely useful as a tool for screening
blood samples from large numbers of HBV carriers for the
presence of HBV pre-C and BCP mutations. Based on our and
others’ findings demonstrating an association between BCP
mutations and liver cancer or cirrhosis, this assay may have
important clinical applications as a screening tool in assessing
an individual’s risk for HCC and also could prove an invaluable
tool for conducting epidemiology studies in areas of HBV
endemicity with the highest HBV burden of liver disease but
with limited resources to carry out expensive and sophisticated
laboratory tests.
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